Loading...

Takeda Pharmaceutical Co Ltd
TSE:4502

Watchlist Manager
Takeda Pharmaceutical Co Ltd Logo
Takeda Pharmaceutical Co Ltd
TSE:4502
Watchlist
Price: 4 171 JPY Market Closed
Updated: Feb 6, 2023

Intrinsic Value

The intrinsic value of one Takeda Pharmaceutical Co Ltd stock under the Base Case scenario is 5 572.72 JPY. Compared to the current market price of 4 171 JPY, Takeda Pharmaceutical Co Ltd is Undervalued by 25%.

The Intrinsic Value is calculated as the average of the two valuation methods:

Intrinsic Value
Base Case
5 572.72 JPY
Undervaluation 25%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

Profitability Score
Profitability Due Diligence

Takeda Pharmaceutical Co Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

Negative 3-Year Average ROIC
Low 3-Year Average ROE
Low ROIC
Low ROE
52/100
Profitability
Score

Takeda Pharmaceutical Co Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Takeda Pharmaceutical Co Ltd's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Average Interest Coverage
Low Altman Z-Score
Positive Net Debt
Short-Term Liabilities
36/100
Solvency
Score

Takeda Pharmaceutical Co Ltd's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Financials
Efficiency
68%
Gross Margin
10%
Operating Margin
6%
Net Margin
21%
FCF Margin
4%
ROE
3%
ROIC
Other

Capital Structure
Takeda Pharmaceutical Co Ltd

Market Capitalization 6.5T JPY
Total Debt 4.2T JPY
Minority Interest 560M JPY
Preferred Equity 0 JPY
Cash and Equivalents 798B JPY
Short-Term Investments 31.9B JPY
Enterprise Value 9.8T JPY

Wall St
Price Targets

Price Targets Summary
Takeda Pharmaceutical Co Ltd

Wall Street analysts forecast Takeda Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Takeda Pharmaceutical Co Ltd is 4 702.84 JPY with a low forecast of 3 737 JPY and a high forecast of 7 245 JPY.

Lowest
Price Target
3 737 JPY
10% Downside
Average
Price Target
4 702.84 JPY
13% Upside
Highest
Price Target
7 245 JPY
74% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Competitors
Takeda Pharmaceutical Co Ltd

Suppliers & Customers
Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd has 107 key suppliers from 13 countries and 17 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.

United States of America
53
Johnson & Johnson
Pharmaceuticals
Evercore Inc
Financial Services
Omnicom Group Inc
Media
UiPath Inc
Technology
Charles River Laboratories International Inc
Life Sciences Tools & Services
Alexandria Real Estate Equities Inc
Real Estate
Ligand Pharmaceuticals Inc
Biotechnology
Xenetic Biosciences Inc
Biotechnology
Alnylam Pharmaceuticals Inc
Biotechnology
R
Royalty Pharma PLC
Pharmaceuticals
9
908 Devices Inc.
Electrical Equipment
Schrodinger Inc
Health Care
Regenxbio Inc
Biotechnology
Incyte Corp
Biotechnology
Infinity Pharmaceuticals Inc
Biotechnology
Halozyme Therapeutics Inc
Biotechnology
E
Elevation Oncology Inc
Biotechnology
Certara Inc
Health Care
Biomarin Pharmaceutical Inc
Biotechnology
Exelixis Inc
Biotechnology
Arcturus Therapeutics Holdings Inc
Biotechnology
Selecta Biosciences Inc
Biotechnology
Moderna Inc
Biotechnology
LogicBio Therapeutics Inc
Biotechnology
Nektar Therapeutics
Pharmaceuticals
P
Prometheus Biosciences Inc
Biotechnology
Neurocrine Biosciences Inc
Biotechnology
Rhythm Pharmaceuticals Inc
Biotechnology
Ovid Therapeutics Inc
Biotechnology
ADMA Biologics Inc
Biotechnology
Sangamo Therapeutics Inc
Biotechnology
Mirum Pharmaceuticals Inc
Biotechnology
Phathom Pharmaceuticals Inc
Pharmaceuticals
F
Finch Therapeutics Group Inc
Biotechnology
Shattuck Labs Inc
Biotechnology
Codexis Inc
Life Sciences Tools & Services
X
XOMA Corp
Biotechnology
Novavax Inc
Biotechnology
T
Theseus Pharmaceuticals Inc
Pharmaceuticals
Biogen Inc
Biotechnology
D
Denali Therapeutics Inc
Biotechnology
Poseida Therapeutics Inc
Biotechnology
Molecular Templates Inc
Biotechnology
R
Recursion Pharmaceuticals Inc
Biotechnology
D
Day One Biopharmaceuticals Inc
Biotechnology
Y
Y-mAbs Therapeutics Inc
Biotechnology
Supernus Pharmaceuticals Inc
Pharmaceuticals
Arrowhead Pharmaceuticals Inc
Biotechnology
Twist Bioscience Corp
Biotechnology
Blackline Inc
Technology
I
Immune Pharmaceuticals Inc
Biotechnology
Seagen Inc
Biotechnology
H
Hillevax Inc
Biotechnology
Suppliers Map

Takeda Pharmaceutical Co Ltd has 54 key customers from 9 countries and 7 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.

Customers Map

Shareholder Return

Price
Takeda Pharmaceutical Co Ltd

1M 1M
+2%
6M 6M
+11%
1Y 1Y
+24%
3Y 3Y
+6%
5Y 5Y
-15%
Annual Price Range
4 171
52w Low
3 209.8141
52w High
4 220
Price Metrics
Average Annual Return -8.46%
Standard Deviation of Annual Returns 22.8%
Max Drawdown -49%
Shares Statistics
Market Capitalization 6.5T JPY
Shares Outstanding 1 571 786 000
Percentage of Shares Shorted
N/A

Company Profile

Takeda Pharmaceutical Co Ltd

Country

Japan

Industry

Pharmaceuticals

Market Cap

6.5T JPY

Dividend Yield

4.42%

Description

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,347 full-time employees. The firm is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The firm's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The firm is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Contact

TOKYO-TO
Chuo-Ku
4F, 2-1-1, Nihombashihon-cho
+81332782111.0
https://www.takeda.com/

IPO

1949-05-16

Employees

47 347

Officers

Pres, CEO & Representative Director
Mr. Christophe Weber
CFO & Representative Director
Mr. Constantine Saroukos
Pres of R&D and Representative Director
Dr. Andrew S. Plump
Chair of Management Board
Dr. Seigo Izumo
Member of Management Board
Mr. Haruhiko Hirate
Member of Management Board and Head of R&D Global Science & Biomedical Policy
Salvatore Alesci
Show More
Chief Accounting Officer & Corp. Controller
Norimasa Takeda
Sr. VP of Corp. Fin. & Controlling Department
Mr. Iwaaki Taniguchi
Chief Data & Technology Officer
Mr. Gabriele Ricci
Global Head of Investor Relations & Global Fin.
Mr. Christopher David O'Reilly
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one Takeda Pharmaceutical Co Ltd stock?

The intrinsic value of one Takeda Pharmaceutical Co Ltd stock under the Base Case scenario is 5 572.72 JPY.

Is Takeda Pharmaceutical Co Ltd stock undervalued or overvalued?

Compared to the current market price of 4 171 JPY, Takeda Pharmaceutical Co Ltd is Undervalued by 25%.